Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracellular Vesicles | 3 | 2021 | 54 | 1.640 |
Why?
|
| Melanoma | 3 | 2024 | 140 | 1.580 |
Why?
|
| Antigens, Neoplasm | 2 | 2024 | 57 | 1.510 |
Why?
|
| Wnt Signaling Pathway | 6 | 2021 | 68 | 1.340 |
Why?
|
| Serpins | 4 | 2024 | 31 | 1.210 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 147 | 1.110 |
Why?
|
| Fibroblasts | 2 | 2018 | 160 | 1.000 |
Why?
|
| Exosomes | 2 | 2017 | 96 | 0.920 |
Why?
|
| Dermatitis | 1 | 2023 | 7 | 0.800 |
Why?
|
| Arthritis | 1 | 2023 | 29 | 0.800 |
Why?
|
| Uveitis | 1 | 2023 | 23 | 0.790 |
Why?
|
| Skin | 3 | 2021 | 155 | 0.760 |
Why?
|
| Trypsin Inhibitor, Bowman-Birk Soybean | 7 | 2002 | 7 | 0.740 |
Why?
|
| Nevus | 1 | 2021 | 4 | 0.700 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 16 | 0.700 |
Why?
|
| Tubular Sweat Gland Adenomas | 1 | 2021 | 1 | 0.690 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2021 | 1 | 0.690 |
Why?
|
| Purpura | 1 | 2021 | 3 | 0.690 |
Why?
|
| Buttocks | 1 | 2021 | 7 | 0.680 |
Why?
|
| Sacrum | 1 | 2021 | 25 | 0.670 |
Why?
|
| Skin Diseases | 2 | 2020 | 30 | 0.670 |
Why?
|
| Dermatitis, Atopic | 1 | 2018 | 2 | 0.570 |
Why?
|
| Emollients | 1 | 2018 | 2 | 0.570 |
Why?
|
| Collagen Type VII | 1 | 2018 | 1 | 0.560 |
Why?
|
| Humans | 26 | 2024 | 29096 | 0.550 |
Why?
|
| Cell Proliferation | 2 | 2021 | 828 | 0.550 |
Why?
|
| Peptides, Cyclic | 6 | 2003 | 30 | 0.520 |
Why?
|
| Dermatology | 1 | 2017 | 15 | 0.510 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 14 | 0.510 |
Why?
|
| Lymphopoiesis | 1 | 2017 | 22 | 0.510 |
Why?
|
| Microbiota | 1 | 2018 | 98 | 0.500 |
Why?
|
| Wnt Proteins | 1 | 2017 | 43 | 0.500 |
Why?
|
| Hemosiderin | 1 | 2016 | 2 | 0.480 |
Why?
|
| Nails | 1 | 2016 | 3 | 0.480 |
Why?
|
| Nail Diseases | 1 | 2016 | 3 | 0.480 |
Why?
|
| Scleroderma, Systemic | 1 | 2016 | 29 | 0.470 |
Why?
|
| Dermatomyositis | 1 | 2016 | 60 | 0.470 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 484 | 0.460 |
Why?
|
| Cell Movement | 1 | 2017 | 377 | 0.460 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 287 | 0.440 |
Why?
|
| Cell Differentiation | 1 | 2017 | 429 | 0.430 |
Why?
|
| Hemorrhage | 1 | 2016 | 266 | 0.410 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 48 | 0.400 |
Why?
|
| Wound Healing | 1 | 2014 | 126 | 0.390 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2004 | 13 | 0.320 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 646 | 0.320 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 415 | 0.310 |
Why?
|
| Mice, Transgenic | 5 | 2024 | 514 | 0.300 |
Why?
|
| Chymotrypsin | 2 | 2000 | 4 | 0.290 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 379 | 0.280 |
Why?
|
| Rheumatic Diseases | 1 | 2008 | 33 | 0.270 |
Why?
|
| Female | 9 | 2021 | 15748 | 0.270 |
Why?
|
| Infant | 2 | 2023 | 1062 | 0.260 |
Why?
|
| Male | 6 | 2023 | 14057 | 0.260 |
Why?
|
| Aged | 4 | 2021 | 5627 | 0.250 |
Why?
|
| Adult | 5 | 2021 | 8081 | 0.250 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2070 | 0.240 |
Why?
|
| Methotrexate | 2 | 2023 | 36 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 346 | 0.230 |
Why?
|
| Threonine | 3 | 2003 | 21 | 0.230 |
Why?
|
| Protease Inhibitors | 3 | 2007 | 40 | 0.220 |
Why?
|
| Oligopeptides | 3 | 2002 | 97 | 0.220 |
Why?
|
| Pancreatic Elastase | 2 | 2007 | 8 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2008 | 486 | 0.220 |
Why?
|
| Protein Conformation | 7 | 2005 | 259 | 0.210 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 1 | 0.210 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2002 | 11 | 0.210 |
Why?
|
| Trypsin | 3 | 2007 | 24 | 0.210 |
Why?
|
| Amino Acid Sequence | 8 | 2004 | 697 | 0.210 |
Why?
|
| Mice | 8 | 2024 | 4848 | 0.210 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2023 | 7 | 0.200 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 20 | 0.200 |
Why?
|
| Pruritus | 1 | 2023 | 8 | 0.200 |
Why?
|
| Granuloma | 1 | 2023 | 18 | 0.200 |
Why?
|
| Retinal Neovascularization | 2 | 2013 | 21 | 0.200 |
Why?
|
| Models, Molecular | 7 | 2007 | 453 | 0.200 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2023 | 3 | 0.200 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2018 | 8 | 0.190 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 11 | 0.190 |
Why?
|
| Cells, Cultured | 2 | 2017 | 1023 | 0.190 |
Why?
|
| Mutation | 3 | 2023 | 873 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2024 | 171 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2024 | 176 | 0.180 |
Why?
|
| Hydrolysis | 6 | 2007 | 60 | 0.180 |
Why?
|
| Endothelial Cells | 2 | 2017 | 373 | 0.180 |
Why?
|
| Prognosis | 1 | 2024 | 815 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2019 | 12 | 0.180 |
Why?
|
| Basement Membrane | 1 | 2021 | 6 | 0.170 |
Why?
|
| Thrombosis | 1 | 2023 | 150 | 0.170 |
Why?
|
| Skin Diseases, Vascular | 1 | 2021 | 3 | 0.170 |
Why?
|
| Calciphylaxis | 1 | 2021 | 4 | 0.170 |
Why?
|
| Animals | 10 | 2024 | 10770 | 0.170 |
Why?
|
| Complement Activation | 1 | 2021 | 27 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2021 | 69 | 0.170 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 44 | 0.170 |
Why?
|
| Incidence | 2 | 2023 | 574 | 0.170 |
Why?
|
| Inpatients | 1 | 2021 | 60 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2021 | 83 | 0.160 |
Why?
|
| Biopsy | 1 | 2021 | 208 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2019 | 12 | 0.150 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 15 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 251 | 0.150 |
Why?
|
| Proteomics | 1 | 2021 | 198 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 481 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 41 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 151 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2021 | 297 | 0.150 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 19 | 0.140 |
Why?
|
| Middle Aged | 3 | 2021 | 7458 | 0.140 |
Why?
|
| Molecular Sequence Data | 5 | 2003 | 1057 | 0.140 |
Why?
|
| Epidermolysis Bullosa | 1 | 2018 | 2 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 166 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 172 | 0.140 |
Why?
|
| Peptide Library | 4 | 2007 | 26 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 33 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2023 | 2651 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 68 | 0.140 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 2 | 2014 | 3 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2021 | 1207 | 0.130 |
Why?
|
| Binding Sites | 6 | 2004 | 355 | 0.130 |
Why?
|
| Wnt3A Protein | 1 | 2017 | 6 | 0.130 |
Why?
|
| Culture Media, Conditioned | 1 | 2017 | 31 | 0.130 |
Why?
|
| Tetraspanin 30 | 1 | 2017 | 7 | 0.130 |
Why?
|
| Chickens | 1 | 2017 | 62 | 0.130 |
Why?
|
| Kinetics | 5 | 2004 | 553 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 413 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2017 | 140 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 286 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 285 | 0.110 |
Why?
|
| Child | 1 | 2021 | 2341 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2014 | 28 | 0.110 |
Why?
|
| beta Catenin | 1 | 2014 | 67 | 0.110 |
Why?
|
| Lithium | 1 | 2014 | 8 | 0.100 |
Why?
|
| Hair Follicle | 1 | 2014 | 10 | 0.100 |
Why?
|
| Young Adult | 1 | 2021 | 2856 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 43 | 0.100 |
Why?
|
| Adolescent | 1 | 2021 | 3239 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 31 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2014 | 87 | 0.100 |
Why?
|
| Serine Endopeptidases | 2 | 2004 | 19 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 81 | 0.100 |
Why?
|
| Microcirculation | 1 | 2014 | 113 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 148 | 0.100 |
Why?
|
| Protein Binding | 3 | 2000 | 667 | 0.100 |
Why?
|
| Stem Cells | 1 | 2013 | 123 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 405 | 0.090 |
Why?
|
| Peptides | 3 | 2005 | 297 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 112 | 0.090 |
Why?
|
| Protein Structure, Secondary | 3 | 2001 | 130 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2014 | 1485 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 882 | 0.070 |
Why?
|
| Biotin | 2 | 2000 | 25 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2008 | 18 | 0.070 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 31 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 36 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2004 | 209 | 0.070 |
Why?
|
| Nanostructures | 1 | 2008 | 64 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 525 | 0.060 |
Why?
|
| Leukocyte Elastase | 2 | 2001 | 6 | 0.050 |
Why?
|
| Models, Chemical | 2 | 2003 | 90 | 0.050 |
Why?
|
| Ulcer | 1 | 2023 | 5 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2023 | 6 | 0.050 |
Why?
|
| Weight Loss | 1 | 2024 | 84 | 0.050 |
Why?
|
| Luteinizing Hormone | 2 | 2018 | 57 | 0.050 |
Why?
|
| Cross Reactions | 2 | 2018 | 74 | 0.050 |
Why?
|
| Homeostasis | 1 | 2024 | 122 | 0.050 |
Why?
|
| Overweight | 1 | 2024 | 115 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 144 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2023 | 28 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 77 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 278 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 209 | 0.050 |
Why?
|
| Insulin | 1 | 2024 | 325 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2024 | 669 | 0.040 |
Why?
|
| Drug Stability | 1 | 2001 | 23 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2001 | 30 | 0.040 |
Why?
|
| Trypsin Inhibitors | 1 | 2001 | 1 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 2000 | 17 | 0.040 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 1 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Azathioprine | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 23 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2020 | 18 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 54 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 64 | 0.040 |
Why?
|
| Valine | 1 | 1999 | 13 | 0.040 |
Why?
|
| Gene Library | 1 | 1999 | 45 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 1999 | 151 | 0.040 |
Why?
|
| Biological Products | 1 | 2020 | 67 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 148 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 165 | 0.040 |
Why?
|
| Swine | 1 | 1999 | 238 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2018 | 77 | 0.030 |
Why?
|
| Insecta | 1 | 2018 | 25 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 705 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 256 | 0.030 |
Why?
|
| Epitopes | 1 | 2018 | 185 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 1998 | 216 | 0.030 |
Why?
|
| Disulfides | 1 | 1996 | 34 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 701 | 0.030 |
Why?
|
| Time Factors | 1 | 1999 | 1619 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2007 | 39 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 57 | 0.030 |
Why?
|
| Receptor, TIE-2 | 1 | 2013 | 9 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 202 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 319 | 0.030 |
Why?
|
| Tryptases | 2 | 2004 | 2 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 198 | 0.020 |
Why?
|
| Permeability | 1 | 2013 | 61 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 59 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 585 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 179 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2003 | 55 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 457 | 0.020 |
Why?
|
| Retina | 1 | 2013 | 445 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 1522 | 0.020 |
Why?
|
| Subtilisin | 1 | 2007 | 1 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2007 | 5 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Drug Design | 1 | 2007 | 63 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 182 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2005 | 51 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 42 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 105 | 0.010 |
Why?
|
| Immunization | 1 | 2005 | 133 | 0.010 |
Why?
|
| Antibodies | 1 | 2005 | 125 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 336 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 284 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 66 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2001 | 202 | 0.010 |
Why?
|